Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity
In a 12-week randomized phase IIa trial in adults with obesity, the dual GLP-1/GLP-2 receptor agonist dapiglutide was well tolerated but did not achieve statistically significant weight loss compared with…